Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Article Details
- CitationCopy to clipboard
Feghali M, Venkataramanan R, Caritis S
Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Semin Perinatol. 2014 Dec;38(8):516-22. doi: 10.1053/j.semperi.2014.08.013. Epub 2014 Sep 23.
- PubMed ID
- 25256193 [ View in PubMed]
- Abstract
Despite advances in neonatal care, the burden of preterm birth remains high. Preterm birth is a multifactorial problem, and strategies to identify and treat medical risk factors in early pregnancy have not been effective in reducing preterm birth rates. In a sentinel clinical trial, prophylactic therapy with 17-hydoxyprogesterone caproate (17-OHPC) reduced the risk of recurrent, spontaneous preterm birth in 34% of women. As a result, clinical practice changed and extensive research on 17-OHPC followed. The increasing body of evidence demonstrated a variable efficacy of the drug. This review will examine the plausibility, pharmacology, clinical efficacy, and safety of 17-OHPC when used in the setting of preterm birth prevention. We will also discuss pharmacokinetic and pharmacodynamics data to highlight drug metabolism and mechanism of action, which will help clarify the variability in clinical outcomes and efficacy.
DrugBank Data that Cites this Article
- Drugs
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Hydroxyprogesterone caproate Cytochrome P450 3A4 Protein Humans UnknownSubstrateDetails Hydroxyprogesterone caproate Cytochrome P450 3A5 Protein Humans UnknownSubstrateDetails